Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?Zacks Investment Research • 07/16/26
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?Zacks Investment Research • 06/25/26
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraBusiness Wire • 06/11/26
Silence Therapeutics to Participate in Jefferies Global Healthcare ConferenceBusiness Wire • 05/27/26
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor ConferenceBusiness Wire • 05/12/26
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial ResultsBusiness Wire • 05/07/26
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/16/26
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?Zacks Investment Research • 03/05/26
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 03/05/26
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceBusiness Wire • 11/12/25
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire • 11/06/25
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)Business Wire • 10/23/25
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire • 08/07/25
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraBusiness Wire • 06/12/25
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a BetZacks Investment Research • 06/06/25
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to TradeZacks Investment Research • 05/21/25
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire • 05/08/25